Viread aims at KRW 100 billion sales as exceeding KRW 50 billion only in the first half of the year

The Gilead’s chronic hepatitis type B treatment, ‘Viread(generic name: tenofovir)’ is expected to make a sales record worth of KRW 50 billion only in the first half of the year.

According to the Yuhan Corporation’s company report written by NH Investment & Securities on the basis of the UBIST LIVE data on the 9^th, sales and accumulated sales of Viread were KRW 8.68 billion and KRW 44.51 billio...